Merck Gets China Nod on HPV Shot for Men
Merck's HPV Vaccine Gains Ground in China
U.S. drugmaker Merck & Co has received approval in China for its HPV vaccine's use in males, expanding its market reach despite earlier weak sales in the region. This move marks a potential growth opportunity as Gardasil has been key to Merck's market strategy alongside cancer treatment Keytruda.
This was the stock's second consecutive day of gains.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending ...
WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
Zacks.com on MSN1d
Merck (MRK) Rises Higher Than Market: Key FactsMerck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback